17p-estradiol (1 mg daily) in continuous combination with dydrogesterone (5.10 or 20 mg daily) increases bone mineral density in postmenopausal women
- Authors: Stevenson J.С.1, Teter P.2, Lees В.3
-
Affiliations:
- Imperial College School of Medicine
- National Osteoporosis Center
- Brompton and Harefield NHS Trust
- Issue: Vol 50, No 4 (2001)
- Pages: 67-71
- Section: Original Research
- URL: https://journals.eco-vector.com/jowd/article/view/95650
- DOI: https://doi.org/10.17816/JOWD95650
- ID: 95650
Cite item
Abstract
Although the minimal dose of 17/3-estradiol in hormone replacement regimens was originally considered to be 2 mg a day, it is now increasingly accepted that a lower dose of 1 mg a day is effective in protecting women from the detrimental effects of the menopause. A 1-year, multicentre, double-blind, randomized study was conducted in 214 healthy postmenopausal women in order to assess the effect of 17(3-estradiol (1 mg a day) continuously combined with dydrogesterone (5,10 or 20 mg/day) in preventing bone loss. Bone mineral density (BMD) was evaluable in 177 women who completed the study. In all women, a statistically significant increase from baseline in lumbar vertebrae (L.2~L4) BMD was seen after 6 months (+ 2,4%; p<0,01); this increase was somewhat greater after 12 months (+ 3,6%;p < 0,01). Similar effects were seen in the hip. After 6 months, BMD in the femoral neck, Ward’s triangle and trochanter had increased by 0,20% (not significant [n.s.]), 0,32% (n.s.)and 1,08% (p<0,01), respectively, compared with baseline. Greater increases were again seen after 12 months (+1,16%, + 1,62% and +2,83%, respectively), all of which were statistically significant (p<0,01) compared with baseline. The change in BMD from baseline did not diff er significantly between the three dydrogesterone dosages for either L.2~L4 or hip. All dosages were well tolerated and amenorrhoea was achieved in over 70%. In conclusion, 17(3-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) results in a significant increase in lumbar vertebrae and hip BMD in postmenopausal women. The lower dose of oestrogen and the avoidance of cyclical bleeding make this a particularly suitable regimen for the prevention and treatment of osteoporosis in older women.
Keywords
Full Text
About the authors
J. С. Stevenson
Imperial College School of Medicine
Author for correspondence.
Email: info@eco-vector.com
United Kingdom, London
P. Teter
National Osteoporosis Center
Email: info@eco-vector.com
Poland, Warsaw
В. Lees
Brompton and Harefield NHS Trust
Email: info@eco-vector.com
United Kingdom, London